TB-500 in Australia: What It Is and How It Is Tested
TB-500 is a lab-made peptide copying seven amino acids of thymosin beta-4, and Australian Research Peptides supplies it across Australia to laboratories and researchers as a single freeze-dried vial posted from Sydney. The fragment copies only the actin-binding stretch of its 43-residue parent protein. Its identity is confirmed by HPLC and mass spectrometry, and the weight difference lets a laboratory tell the short fragment from the full protein. Supplied for in vitro research purposes only.
4 minute read
What Is TB-500?
TB-500 is a synthetic peptide made of seven amino acids, written Ac-LKKTETQ, that reproduces one short stretch of a naturally occurring protein called thymosin beta-4. The “Ac” is an acetyl group capping the front end of the chain.
Chemists call a seven-residue chain a heptapeptide. Buyers type the name several ways — TB500, TB 500, TB-500 — and all of them mean the same short fragment. PubChem indexes it as a single compound record, with a free-acid molecular weight of about 889 g/mol.
Is TB-500 the Same as Thymosin Beta-4?
TB-500 is not the same as thymosin beta-4. Thymosin beta-4 is a protein of 43 amino acids weighing roughly 5 kDa, and TB-500 copies only seven of them — the stretch at positions 17 to 23 that holds on to actin.
For a buyer that has two practical consequences. First, a paper about the whole protein is not automatically a paper about the fragment, so a claim should be traced to the molecule it was measured on. Second, the size gap is large enough that a laboratory can tell the two apart by weight alone, which is the subject of the testing section below. BPC-157 vs TB-500 walks through the parent-protein question in more depth.
What Does the Research Literature Study TB-500 For?
Published TB-500 research is preclinical — cell culture and animal models — and it centres on actin, the protein a cell assembles into its internal scaffolding. The fragment binds single, unassembled actin units, and that one property is why it was isolated at all.
- Actin binding. UniProt annotates thymosin beta-4 as binding and sequestering actin monomers, which holds back their assembly into filaments.
- Blood-vessel formation assays. A 2003 FASEB Journal study by Philp and colleagues reported that the seven-residue actin-binding motif was essential to the parent protein’s activity in angiogenesis assays, and that peptides missing any part of the motif were inactive.
- Tissue-repair models. The fragment also appears in animal models of tendon and soft-tissue injury, where it is studied alongside BPC-157.
The record stops at those model systems. TB-500 has not been approved as a medicine by any regulator, and the findings above describe what was measured in glassware and in animals, not an effect in a person.
How Is TB-500 Tested?
TB-500 is tested with two complementary methods: high-performance liquid chromatography (HPLC), which reports how much of the sample runs as one peak, and mass spectrometry, which weighs the molecule to confirm which peptide is present.
| Method | Question it answers | Why it matters for TB-500 |
|---|---|---|
| HPLC | What share of the sample is a single component? | Shows whether the powder is mostly one peptide or a mixture of the target and its by-products |
| Mass spectrometry | Does the molecule weigh what the named peptide should? | Separates the sub-1 kDa fragment from the roughly 5 kDa parent protein, and catches a chain that has lost its acetyl cap |
The TB-500 that Australian Research Peptides lists carries the HPLC Verified grade: the material is analysed by a laboratory independent of both ARP and the manufacturer before it is released for sale. A result describes the batch that was analysed, not the product line in general.
No TB-500 certificate is on file in the CoA library yet; reports are published there as they become available. Peptide testing, purity and CoAs explains how to read one line by line.
How Is TB-500 Supplied in Australia?
Australian Research Peptides supplies TB-500 to laboratories and researchers in one strength, 10 mg, as freeze-dried powder under a tamper-evident seal, and posts it within Australia so a parcel never passes through customs.
The TB-500 listing is out of stock at the moment, and it offers a single email alert for when a batch lands. The dry powder keeps best sealed, frozen and out of bright light until the day it is used. TB-500 is also one of the two peptides in the BPC-157 + TB-500 blend, which is a separate listing with its own batch record.
Common Questions
Laboratories and researchers in Australia can buy TB-500 from Australian Research Peptides, which lists it as a single 10 mg freeze-dried vial and posts it domestically. The line is currently out of stock; its product page shows availability and takes a restock alert.
TB-500, TB500 and TB 500 are three spellings of one name for the same seven-amino-acid fragment. None of them is a different compound. The formal description is the N-terminally acetylated 17–23 fragment of thymosin beta-4.
A mass spectrometry test can tell TB-500 from thymosin beta-4, because the fragment weighs under 1 kDa and the full protein about 5 kDa. The two cannot be confused on the instrument, whatever a label says.
Laboratories and researchers can order TB-500 from Australian Research Peptides as one freeze-dried vial in its Tissue Repair Research range, currently awaiting its next batch, posted within Australia from Sydney. For in vitro research purposes only.
References
Read this article as plain text — TB-500 in Australia: What It Is and How It Is Tested, in Markdown — the full text in Markdown, without the page around it, for assistants, screen readers and offline reading.